YM 58483 (BTP2) for SOCE Research

Store-operated calcium entry (SOCE) links intracellular calcium-store depletion to sustained calcium influx. Because this pathway supports transcription, cytokine production, secretion, and remodeling in many non-excitable cells, a carefully controlled SOCE blocker can help separate calcium-dependent effects from receptor-proximal signaling. YM 58483 (BTP2), a store-operated Ca2+ entry (SOCE) blocker, is supplied by APExBIO for research applications involving calcium signaling, T-cell biology, and immune-associated tissue injury.

Setup/Principle overview

In a typical SOCE response, depletion of endoplasmic-reticulum calcium promotes activation of the STIM–ORAI system and calcium influx through calcium release-activated calcium channels. Other calcium-permeable channels, including transient receptor potential (TRP) channels, can also contribute to the sustained phase. YM 58483, also called BTP2, suppresses this influx, making it useful for testing whether a phenotype depends on continued calcium entry rather than on the initiating stimulus alone.

The distinction is experimentally important. Early receptor signaling may remain intact while downstream calcium-sensitive transcription is reduced. In T cells, this can be evaluated with a T cell activation assay that combines a functional stimulus with calcium imaging, NFAT activity, and cytokine measurement. The product information reports dose-dependent inhibition of PHA-induced IL-2 production, with an IC50 of approximately 17 nM, and inhibition of NF-AT-driven promoter activity without affecting AP-1-driven activity. These values should guide, rather than replace, a laboratory-specific dose-response experiment.

YM 58483 is a solid compound with a reported molecular weight of 421.32 and formula C15H9F6N5OS. It is insoluble in water but soluble in DMSO and ethanol at high concentrations, according to the product information. Store the solid at −20 °C, prepare concentrated stocks in a compatible solvent, and use diluted solutions promptly.

Key Innovation from the Reference Study

The study ORAI2 is Important for the Development of Early-Stage Postirradiation Fibrosis in Salivary Glands moves SOCE analysis beyond an immune-cell endpoint. The investigators combined primary human submandibular gland cells, irradiated C57BL/6J mouse glands, RNA sequencing, pharmacologic SOCE inhibition with SKF96365 and YM58483, and pathway analysis. After 15 Gy irradiation, they identified ORAI2-associated calcium signaling as an early component of gland fibrosis. Their mechanistic model connected SOCE to JNK/NFAT1 signaling and increased TGF-β1, a central fibrogenic mediator.

The practical innovation is the pairing of a pathway inhibitor with both molecular and tissue-level endpoints. Rather than treating a reduction in collagen markers as proof of direct channel inhibition, researchers can measure calcium entry, NFAT1-related transcription, TGF-β1 expression, myofibroblast-associated markers, histology, and gland function in parallel. In the reported mouse model, SOCE inhibition reduced fibrosis 30 days after irradiation, while pharmacologic NFAT1 inhibition restored saliva flow to 84.61% of normal levels without detectable side effects during the study period. These findings support YM 58483 as a mechanistic probe, not as evidence of a ready-to-use clinical treatment.

For assay design, the paper suggests three useful choices: use an early postirradiation time point when testing pathway activation, include ORAI2 expression or localization measurements when assigning channel involvement, and retain a functional endpoint such as saliva flow or secretion alongside molecular markers. A drug-only experiment cannot establish ORAI2 specificity because YM 58483 acts at the SOCE level and may affect multiple channel components.

Step-by-step workflow and protocol enhancements

1. Define the biological question

Start by deciding whether the experiment asks, “Does sustained calcium entry support this phenotype?” or the narrower question, “Is ORAI2 responsible?” YM 58483 is well suited to the first question. The second requires additional evidence, such as ORAI2 abundance, loss-of-function approaches, rescue experiments, or channel-resolved electrophysiology. This distinction prevents overinterpretation of a pharmacologic response.

2. Build a concentration-response design

For immune-cell work, center the initial range around the reported IL-2 inhibition value. A serial dilution can reveal whether NFAT activity, calcium influx, and IL-2 production shift together. Include vehicle-matched wells, unstimulated cells, stimulated cells without inhibitor, and a viability readout. A strong response should be accompanied by preserved cell integrity; otherwise, reduced cytokine production may reflect nonspecific toxicity.

3. Separate calcium entry from calcium release

Use a two-stage calcium experiment when possible. Record the response to the activating stimulus under calcium-reduced conditions to assess intracellular-store release, then restore extracellular calcium and quantify the sustained influx phase. YM 58483 should primarily reduce the second phase in an appropriately configured SOCE assay. This design is more informative than a single endpoint measured after total stimulation.

4. Connect proximal signaling to phenotype

In a T cell activation assay, pair calcium imaging with NFAT reporter activity and IL-2 production inhibition. In salivary gland or stromal models, combine calcium measurements with NFAT1, TGF-β1, extracellular-matrix, and myofibroblast-related readouts. If the inhibitor suppresses phenotype but not calcium entry, investigate assay timing, compound exposure, and alternative calcium routes before assigning a SOCE mechanism.

Protocol Parameters

• Stock preparation: As a practical starting condition, dissolve YM 58483 at 10 mM in DMSO; for the reported molecular weight, this corresponds to approximately 4.21 mg/mL. Aliquot at −20 °C and minimize repeated freeze-thaw cycles.
• Initial dose series: Test 1, 3, 10, 30, and 100 nM for immune-cell assays, with a 30-minute pretreatment at 37 °C before stimulation. This range brackets the reported IL-2 IC50 of approximately 17 nM while allowing for cell-type differences.
• Vehicle control: Keep final DMSO at or below 0.1% v/v in every well, including untreated controls, and use a 100 µL final assay volume when adapting the workflow to a 96-well plate.
• Calcium-entry recording: For a proposed imaging workflow, collect a 5-minute baseline, apply the stimulus, and record for at least 10 minutes after extracellular calcium restoration at 37 °C. Analyze the sustained-area-under-the-curve separately from the peak release response.
• Radiation-associated fibrosis model: If reproducing the reference framework, use the reported 15 Gy irradiation condition and assess early fibrosis-related changes at the 30-day endpoint; maintain matched sham-irradiated and vehicle-treated groups.

The first four parameters are workflow starting points that should be optimized for cell density, stimulus strength, plate format, and detector sensitivity. The 15 Gy and 30-day conditions are tied specifically to the referenced salivary gland model and should not be transferred automatically to other tissues.

Advanced applications and comparative advantages

Immune-cell signaling

BTP2 is particularly useful when the objective is to connect calcium influx with T-cell transcription. NFAT-sensitive reporters can be measured alongside AP-1-sensitive controls to determine whether inhibition is pathway-biased. Cytokine measurements add biological relevance, but a single IL-2 endpoint is insufficient to distinguish altered transcription from reduced viability, impaired stimulation, or delayed secretion.

The compound also supports studies in macrophages, basophils, dendritic cells, and mast cells, where sustained calcium signals regulate activation or secretory behavior. Since SOCE channels include both highly calcium-selective CRAC channels and non-selective TRP channels, experiments described as inhibition of CRAC channels or inhibition of TRP channels should include appropriate channel-expression and functional controls. YM 58483 can identify SOCE dependence, but it should not be presented as a substitute for channel-specific genetic or biophysical validation.

Fibrosis and gland-injury models

The salivary gland study provides a differentiated use case: testing whether calcium signaling contributes to fibrosis before structural remodeling becomes irreversible. In this setting, YM 58483 can be integrated with irradiated primary cells or mouse tissue, followed by pathway and functional analysis. The advantage is mechanistic breadth: the same perturbation can be examined at calcium, transcriptional, matrix, histologic, and secretion levels.

The article YM 58483 (BTP2): Advanced SOCE Blockade for Fibrosis and Immune Modulation complements this workflow by emphasizing how SOCE inhibition can be organized across immune and fibrosis assays. A related resource, YM 58483 (BTP2) in Applied SOCE Blockade for Fibrosis Models, extends the same concept toward assay optimization. These resources are useful as application-oriented complements; the peer-reviewed salivary gland study remains the basis for the ORAI2/JNK/NFAT1/TGF-β1 interpretation.

Why this cross-domain matters, maturity, and limitations

Immune signaling and radiation-associated fibrosis share a dependence on calcium-sensitive transcription, but they are not interchangeable models. A concentration that suppresses IL-2 in lymphocytes may not produce the same exposure-response relationship in primary gland cells or fibroblast-like populations. Likewise, a reduction in TGF-β1 after irradiation does not prove that the compound directly prevents tissue fibrosis through ORAI2.

The mature conclusion is that SOCE inhibition is a useful perturbation for testing calcium dependence across these systems. The less mature conclusion is therapeutic translation. The reference study supports an ORAI2/JNK/NFAT1/TGF-β1 axis in early salivary gland fibrosis, while the product dossier supports use in calcium signaling and immune-response research. Neither source establishes dosing, safety, or efficacy in human disease. Include pharmacokinetic, tissue-exposure, and off-target studies before making translational claims.

Troubleshooting and optimization tips

• No reduction in the sustained calcium phase: Confirm compound dilution, mixing, and exposure time first. Because the water-insoluble compound can precipitate after aqueous dilution, inspect wells and prepare fresh working solutions. Verify that the assay actually generates store depletion and that extracellular calcium is restored at the intended time.
• Large loss of viability: Reduce the concentration range or shorten pretreatment, then compare viability with the calcium and cytokine endpoints. Check that the DMSO concentration is identical across conditions. A decrease in IL-2 without preserved viability is not strong evidence for selective IL-2 production inhibition.
• Peak release is inhibited unexpectedly: The design may be measuring intracellular calcium release and SOCE simultaneously. Add a calcium-free or calcium-reduced phase and analyze peak and sustained components separately. Confirm that YM 58483 was added before the entry phase rather than after the signal had already developed.
• NFAT and AP-1 both decline: This pattern may reflect excessive inhibitor exposure, weak stimulation, or general transcriptional suppression. Repeat the dose series, normalize reporter activity to viability, and include an unstimulated baseline. The reported separation between NFAT and AP-1 should be treated as a benchmark, not a guarantee in every cell line.
• Fibrosis markers change without functional recovery: Extend the endpoint panel to include tissue architecture and secretion. In the salivary gland model, functional saliva flow was important because molecular improvement alone may not represent restoration of gland performance.
• ORAI2 mechanism remains ambiguous: Measure ORAI2 alongside other SOCE-associated components and compare pharmacologic results with genetic perturbation. YM 58483 establishes pathway dependence more readily than individual-channel specificity.

Future outlook

Future work can build directly on the evidence already available by aligning SOCE measurements with ORAI2, JNK, NFAT1, and TGF-β1 across earlier and later stages of radiation-associated gland injury. The most informative studies will retain orthogonal endpoints: real-time calcium entry, transcriptional activity, fibrosis markers, histology, and gland function. This approach can clarify whether calcium blockade acts primarily by preventing early signaling, limiting feed-forward fibrogenesis, or preserving secretory cells.

For immunology, the same principle favors multiplexed designs that compare NFAT-linked transcription, AP-1 activity, IL-2 production, and viability rather than relying on one endpoint. YM 58483 (BTP2) is therefore best positioned as a controlled mechanistic probe: it can reveal when sustained SOCE is necessary, identify responsive cell states, and help prioritize ORAI2-centered hypotheses for more specific validation. Its value will depend on disciplined controls, transparent exposure conditions, and careful separation of pathway inhibition from nonspecific cellular stress.